Table 2.
Summaries of used studies
| Posology | Observed data | Simulated data | ||||||
|---|---|---|---|---|---|---|---|---|
| Drug | Scheme | Dose | n | Reference | Population | n | Population | Figure |
| TFV | i.v. single dose | 1 mg kg−1 (1 h) | 8 | Deeks et al. 28 | 100 | 2, 3 | ||
| TFV | i.v. single dose | 8 mg kg−1 | 7 | Deeks et al. 28 | 100 | 3 | ||
| TDF | oral single dose | 300 mg | 9 | Wenning et al. 39 | 100 | 2, 3 | ||
| 3TC | i.v. single dose | 0.25 mg kg−1 | 4 | Johnson et al. 21 | 100 | 3 | ||
| 3TC | i.v. single dose | 1 mg kg−1 | 4 | Johnson et al. 21 | 100 | 3 | ||
| 3TC | i.v. single dose | 2 mg kg−1 | 4 | Johnson et al. 21 | HIV infected males | 100 | age: 20–50 years, male | 3 |
| 3TC | i.v. single dose | 8 mg kg−1 | 4 | Johnson et al. 21 | 100 | 2, | ||
| 3TC | oral single dose | 0.25 mg kg−1 | 10 | Johnson et al. 21 | 100 | 3 | ||
| 3TC | oral single dose | 0.5 mg kg−1 | 12 | Johnson et al. 21 | 100 | 3 | ||
| 3TC | oral single dose | 1 mg kg−1 | 14 | Johnson et al. 21 | 100 | 3 | ||
| 3TC | oral single dose | 2 mg kg−1 | 9 | Johnson et al. 21 | 100 | 3 | ||
| 3TC | oral single dose | 6 mg kg−1 | 15 | Johnson et al. 21 | 100 | 3 | ||
| 3TC | oral single dose | 10 mg kg−1 | 14 | Johnson et al. 21 | 100 | 3 | ||
| 3TC | oral single dose | 150 mg | 24 | Johnson et al. 21 | Healthy volunteers | 100 | 2, 3 | |
| FTC | oral steady-state, twice daily | 25 mg | 8 | Wang et al. 38 | 100 | 3 | ||
| FTC | oral steady-state, twice daily | 100 mg | 8 | Wang et al. 38 | HIV infected males and females | 100 | age: 20–50 years prop.F = 0.5 | 3 |
| FTC | oral steady-state, once daily | 100 mg | 8 | Wang et al. 38 | 100 | 3 | ||
| FTC | oral steady-state, twice daily | 200 mg | 8 | Wang et al. 38 | 100 | 2,3 | ||
| FTC | oral steady-state, once daily | 200 mg | 8 | Wang et al. 38 | 100 | 3 | ||
| TDF | oral steady-state, once daily | 300 mg | 46 | Benaboud et al. 26 | Pregnant women | 100 | Pregnant women 0 < GA < 40 weeks | 4 |
| TDF | oral single dose | 600 mg | 38 | Hirt et al. 23 | Women in labour | 100 | Pregnant women 0 < GA < 40 weeks | 4 |
| 33 < GA < 42 weeks (median = 39 weeks) | age: 20–45 years | |||||||
| TDF | oral steady-state, once daily | 300 mg | 34 | Colbers et al. 42 | Pregnant women | 100 | Pregnant women GA = 33 weeks | 4,5 |
| age: 20–45 years | ||||||||
| 28 < GA < 38 weeks (median = 33 weeks) | ||||||||
| TDF | oral steady-stare, once daily | 300 mg | 19 | Benaboud et al. 26 | Pregnant women | 19 | Pregnant women GA = 33 weeks | 5 |
| 28 < GA < 38 weeks | age: 20–45 years | |||||||
| 3TC | oral steady-state, twice daily | 150 mg | 114 | Benaboud et al. 25 | Pregnant women | 100 | Pregnant women 0 < GA < 40 weeks | 4 |
| 6 < GA < 39 weeks | age: 20–45 years | |||||||
| 3TC | oral steady-state twice daily | 150 mg | 40 | Benaboud et al. 25 | Pregnant women | 40 | Pregnant women GA = 29 weeks | 5 |
| 24 < GA < 34 weeks (median = 29 weeks) | age: 20–45 years | |||||||
| FTC | oral steady-state, twice daily | 200 mg | 83 | Valade et al. 41 | Pregnant women | 100 | Pregnant women 0 < GA < 40 weeks | 4 |
| 5 < GA < 41 weeks (median = 29 weeks) | age: 20–45 years | |||||||
| FTC | oral steady-state, once daily | 200 mg | 27 | Colbers et al. 42 | Pregnant women | 100 | Pregnant women GA = 33 weeks | 4 |
| 28 < GA < 38 weeks (median = 33 weeks) | age: 20–45 years | |||||||
| FTC | oral steady-state, once daily | 200 mg | 26 | Stek et al. 43 | Pregnant women | 100, 26 | Pregnant women GA = 35 weeks | 4, 5 |
| 31 < GA < 38 weeks (median = 35 weeks) | age: 20–45 years | |||||||
GA, gestational age